The amino acid sequences of the C-terminal domain (CTD) of the type II DNA topoisomerases are divergent and species speci®c as compared with the highly conserved N-terminal and central domains. A set of C-terminal deletion mutants of Leishmania donovani topoisomerase II was constructed. Removal of more than 178 amino acids out of 1236 amino acid residues from the C-terminus inactivates the enzyme, whereas removal of 118 amino acids or less has no apparent effect on the ability of the parasite enzyme to complement a temperature-sensitive mutation of the Saccharomyces cerevisiae topoisomerase II gene. Deletion analysis revealed a potent nuclear localization signal (NLS) within the amino acid residues 998±1058. Immunomicroscopy results suggest that the removal of an NLS in the CTD is likely to contribute to the physiological dysfunction of these proteins. Modeling of the LdTOP2 based on the crystal structure of the yeast type II DNA topoisomerase showed that the parasite protein assumes a structure similar to its yeast counterpart harboring all the conserved residues in a structurally similar position. However, a marked difference in electrostatic potential was found in a span of 60 amino acid residues (998±1058), which also do not have any homology with topoisomerase II sequences. Such signi®cant differences can be exploited by the structure-based design of selective inhibitors using the structure of the Leishmania enzyme as a template.
INTRODUCTION
Topoisomerases are enzymes that can modify the tertiary structure of DNA without altering the primary structure (1) .
DNA topoisomerases accomplish their function by either passing one strand of DNA duplex through a transient break in the other strand (type I topoisomerase) resulting in changes in the linking number in steps of one (2) or by a passing a duplex DNA from the same or another molecule through a transient double-stranded break generated in the DNA in an ATPdependent manner (type II topoisomerase), resulting in changes in linking number in steps of two (3) . These enzymes participate in nearly all events related to DNA metabolism which includes replication, transcription and recombination (4) . Eukaryotic type II topoisomerases (TOP2) are also important because of their essential role in chromosome segregation (5) and maintenance of the chromosome structure (6) . In addition to these functions, topoisomerase II is a component of the nuclear scaffold where it is involved in chromosome condensation and decondensation (7, 8) . These enzymes have been found in all cell types from viruses (9) to bacteria (10) to mammals (11) and are essential for cell viability. Recent biochemical and structural studies provide an insight into the mechanistic detail of the eukaryotic topoisomerase II (12) ; however, little information has emerged about the functional organization of the enzyme.
Comparison of the primary sequence suggests that eukaryotic topoisomerase II has evolved by the fusion of the gyr A and gyr B genes of DNA gyrase, the eubacterial counterpart of topoisomerase II. Based on homology to DNA gyrase, topoisomerase II can be divided into three distinct domains. The N-terminal domain is homologous to the gyrase B subunit that contains the ATP binding and hydrolysis activity, the central part is similar to the gyrase A subunit and contains the active site tyrosine which is implicated in the DNA breakage and rejoining reaction. The N-terminal and the central part of topoisomerase II are highly conserved among different eukaryotic species. The conservation decreases markedly at the C-terminus, which is not homologous to either subunit of gyrase and the one-third of the C-terminal domain (CTD) is quite divergent in sequence. The C-terminus is of interest for a number of reasons. First, it is highly hydrophilic and contains the regulatory sequences such as the nuclear localization signal (NLS) (13) , phosphorylation sites and a dimerization interface (14±16). Secondly, while partial proteolysis and truncation analysis of topoisomerase II from human (17) , Drosophila (18) , Schizosaccharomyces pombe (19) and Saccharomyces cerevisiae (20) reveal that the C-terminus is dispensable for the biochemical activities (21) , this domain is thought to enhance the stability of the complex formed between DNA and topoisomerase II (22) .
The kinetoplastid protozoan parasite Leishmania causes a spectrum of disease, termed leishmaniasis, manifesting pathologies from mild to dis®guring to fatal. This protozoan diverged early in the eukaryotic evolution, near the base of the evolutionary tree before the emergence of several protozoan lineages and well before the separation of the crown metazoan lineages that comprise plants, animals and fungi (23) . Work on DNA topoisomerases from the kinetoplastid protozoan parasite has been a major focus of interest, since these enzymes are believed to play an important role in the replication of the unusual kinetoplast DNA (kDNA) harbored in the mitochondrion of these parasites. Type II DNA topoisomerases have been isolated from several kinetoplastid protozoans and the genes encoding these enzymes have been cloned and sequenced in Trypanosoma brucei (24) , Trypanosoma cruzi (25) and Crithidia fasciculata (26) .We have previously reported topoisomerase activity from the cell extracts of Leishmania donovani (27, 28) and the gene encoding the type II DNA topoisomerase was isolated (29) . DNA sequence analysis revealed an ORF of 3711 bp with no introns and encoding a protein of 1236 amino acids. This was shown to be an ATP-dependent enzyme whose activity was inhibited by etoposide, an eukaryotic topoisomerase II inhibitor.
The L.donovani topoisomerase II has the highest degree of homology with the TOP2 of other kinetoplastid parasites. With its human counterpart the LdTOP2 shares a much lower identity of 32% and a similarity of 47%. The degree of homology is much higher towards the N-terminus and gradually falls off towards the C-terminus. Although this domain contains none of the functions known to be necessary for enzyme catalysis, it has been retained in phylogenetically divergent organisms and thus presumably performs some important functions for the enzyme.
In this study, a series of deletion mutants of the TOP2 gene of L.donovani were constructed and introduced into a temperature-sensitive S.cerevisiae strain to investigate the functions of the C-terminus of the enzyme. The mutant proteins were characterized with respect to their complementation ability, stability inside yeast cells and in vitro catalytic activity. Using a molecular modeling approach we examined the plausible structure for the LdTOP2 based on the available crystal structure of yeast type II DNA topoisomerase (12) . We detected signi®cant differences in the charge distribution of the two enzymes in their C-termini. Taken together, our results provide the ®rst insight into the structure and biochemical properties of the CTD of type II DNA topoisomerase from the kinetoplastid protozoan parasite L.donovani. In the CTD, a region has been identi®ed between amino acid residues 998 and 1058, which plays a crucial role in modulating the catalytic activity of the enzyme in vitro and in substituting for the yeast topoisomerase II in vivo.
MATERIALS AND METHODS

Strains, media and growth conditions
The Escherichia coli strains used were DH5a and BL21 (DE3) pLysS. If required, ampicillin and chloramphenicol were used at 100 and 34 mg/ml concentrations, respectively. Wild-type and mutant topoisomerase II of L.donovani were expressed in the yeast strain RS192 that has a genotype of MATa top2-1 top1-8 [top1:: LEU2] ade2 ura3-1 his3-11 trp1-1 leu 2-3 leu2-112 (a gift from Dr Rolf Sternglanz, State University of New York, Stony Brook). The yeast cells were grown at 25°C on YEPD medium containing 1% peptone, 2% yeast extract, 2% dextrose and 1.5% agar or synthetic minimal media containing 6.7 g/l yeast nitrogen base without amino acid, 5 g/l casamino acids, 20 g/l glucose, 20 mg/l adenine sulfate, 20 mg/l tryptophan and 15 g/l Bacto agar (30) .
Construction of mutants
The full-length LdTOP2 gene previously cloned in the HindIII/XbaI site of pBluescript (SK+) (29) was subcloned as a HindIII/XbaI fragment into the yeast shuttle vector pVT100U, a gift from Dr Rolf Sternglanz (31) . For construction of all truncation mutants, the regions corresponding to amino acids 1±1195, 1±1118, 1±1058, 1±998 and 1±785 were ampli®ed by polymerase chain reaction (PCR). In all cases the 5¢ primer was 5A (5¢-CCCAAGCTTATGACAGACGCTTC-CAAG-3¢) and the different 3¢ primers were 3A (5¢-GCT-CTAGAGGAACCGACCAACCGCTT-3¢), 3B (5¢-GCTCTA-GACGAGTTGATGAGCACGCG-3¢), 3C (5¢-GCTCTAGA-GAAGCTCTCGTCCACGCG-3¢), 3D (5¢-GCTCTAGACT-TGTACAAGTCAAGGCG-3¢) and 3E (5¢-GCTCTAGAG-GCAAAACGGCTGAGCTT-3¢). The ampli®ed products were cloned in the HindIII/XbaI site of pVT100U, resulting in constructs LdDC1195, LdDC1118, LdDC1058, LdDC998 and LdDC785, respectively. The mutants LdDC998 and LdDC785 were also cloned in the NdeI/BamHI site of pET 16b (Novagen) and expressed in E.coli BL21 (DE3) pLysS. The different sets of primers used were 5B (5¢-GGGAATTC-CATATGACGCTTCCAAG-3¢) and 3F (5¢-CGGGATCCC-TTGTACAAGTCAAGGCG-3¢) and 3G (5¢-CGGGATCCG-GCAAAACGGCTGAGCTT-3¢), resulting in constructs LdDC998 and LdDC785, respectively. The PCR was performed using 30 cycles of denaturation at 94°C for 45 s, annealing at 54°C for 30 s and extension at 68°C for 1 min/kb with 2.5 U of high-®delity Taq DNA polymerase (Roche Applied Science) and 200 mM of each dNTP. In all cases, the LdTOP2 truncation mutants were under ADH1 promoter in the shuttle vector and under T7 RNA polymerase promotor in pET16b, respectively.
Complementation assay
The yeast strain RS192 was used for transformation with L.donovani topoisomerase II truncation mutants by the lithium acetate and polyethylene glycol method (32) . The transformants were cultured on solid synthetic minimal medium at 25°C for 2 days. The replicated colonies were grown at 37°C for 7 days. Colonies were picked and cultured in tubes with 2 ml of synthetic minimal media at 25°C overnight. The cells were collected and resuspended in a lysis buffer containing 2% Triton X-100, 1% SDS, 100 mM NaCl, 10 mM Tris±HCl and 1 mM EDTA and plasmids were prepared as described (33) .
Reverse transcription (RT±PCR)
Yeast spheroplast was prepared by the method described (30) . Total RNA was isolated using the RNA Isolation Kit (Roche Applied Science) according to the manufacturer's protocol. RT±PCR was performed using a sense primer, 5¢-GGG-AATTCCATATGACAGACGCTTCCAAG-3¢, and an antisense primer, 5¢-CGGGATCCCGCCTCCAGAAACGGCAT-3¢, designed to amplify the N-terminal 1.1 kb of the L.donovani topoisomerase II gene. The PCR program consisted of an initial RT at 42°C for 1 h, followed by the ampli®cation of the cDNA product for 30 cycles at 94°C for 45 s, 52°C for 30 s and 68°C for 1 min using the Titan one tube RT±PCR kit from Roche Applied Science. The resultant RT±PCR products were electrophoresed in 1% agarose gel, stained with ethidium bromide and photographed under UV illumination.
Decatenation assay
Bacterial cells were lysed as described (29) . Brie¯y, the cells were induced at 0.6 OD 600 with 0.5 mM IPTG at 37°C for 3 h. Bacteria were harvested by centrifugation and the cells were resuspended in lysis buffer containing 20 mM Tris±Cl pH 7.8, 100 mM NaCl, 1 mM EDTA, 100 mg of lysozyme (SigmaAldrich), 5 mM DTT, 0.1% (v/v) Triton X-100 and protease inhibitor. Final lysis was achieved by sonication on ice and the lysate was cleared by centrifugation at 12 000 r.p.m. in a SS34 rotor for 15 min. Yeast cells were lysed in a buffer containing 150 mM NaCl, 10 mM Tris±HCl pH 7.9, 1 mM EDTA, 0.1% Triton X-100 and 15 mM b-mercaptoethanol and 300 mg of acid-washed glass beads (300 mm; Sigma-Aldrich) by rapid vortexing (34) . Decatenation assays were performed in total volumes of 25 ml containing 25 mM Tris±HCl pH 7.9, 10 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, 50 mM NaCl, 10% glycerol, 1 mg of kDNA from L.donovani strain UR6 and crude yeast or bacterial extracts. The assays were carried at 30°C for 30 min and the reaction products were analyzed by electrophoresis on a 1% agarose gel as above.
Antibody production and western blotting analysis A 1.1 kb fragment was ampli®ed from the 4.1 kb genomic clone of L.donovani, using a sense primer, 5¢-GGGAATTC-CATATGACAGACGCTTCCAAG-3¢, and an anti-sense primer, 5¢-CGGGATCCCGCCTCCAGAAACGGCAT-3¢, that coded the N-terminal 385 amino acids of the LdTOP2 gene. This fragment was cloned in the NdeI/BamHI site of bacterial expression vector pET 16b and transformed into BL21 (DE3) pLysS. Expression from the construct pET16b/1.1 yielded a 43 kDa protein as viewed by SDS±PAGE (35) . The overexpressed protein band was excised from the gel and the protein was electro-eluted in a buffer containing 200 mM Trisacetate pH 7.4, 1% SDS and 100 mM DTT per 0.1 g of wet gel slice (36) . It was dialyzed against a buffer containing 50 mM Tris-acetate pH 7.4, 0.1% SDS at 100 mA for 3 h. The electroeluted product (100 mg) was subcutaneously injected (36) in rabbit using Freund's complete adjuvant, followed by two injections at 2 week intervals with incomplete adjuvant to produce the polyclonal antibody against the 43 kDa protein.
This serum was then used for western blot analysis and immuno¯uorescence experiments.
For immunoblot analysis, yeast cells harboring the fulllength and truncated LdTOP2 constructs were lysed as previously mentioned. The protein content of cell lysates was estimated by the Bio-Rad Protein Estimation Kit according to the manufacturer's protocol. Twenty micrograms of protein from each cell lysate was loaded in separate lanes and electrophoresed in 8% SDS±polyacrylamide gels. Proteins were transferred to 0.2 mm nitrocellulose membranes using a Bio-Rad wet blotter following the manufacturer's instructions. Antibody probing of membrane blots was carried out as follows. The membrane was blocked with 3% BSA in PBS for 1 h, then incubated for 2 h with 100 times diluted primary antibody (LdTOP2-speci®c polyclonal antibody) in PBS containing 0.1% Tween-20 (PBST). The membrane was washed four times in PBST and incubated with 1000 times diluted alkaline phosphatase-conjugated goat (anti-rabbit) antisera in PBST for 45 min at room temperature. The membrane was washed as above prior to color generation and then incubated in a buffer (100 mM Tris±HCl pH 8.8) containing 330 mg/ml nitroblue tetrazolium and 160 mg/ml 5-bromo-4-chloro-3-indolyl phosphate. Color development was stopped by the addition of a buffer containing 20 mM Tris±HCl, pH 8.0 and 5 mM EDTA.
Immuno¯uorescence microscopy
Yeast strain RS192 containing wild-type and mutant forms of LdTOP2 was prepared for immunostaining as described previously (15) . Brie¯y, the cells were grown at 25°C until an OD 600 of 0.5, and then shifted to 37°C for 4 h. The cells were harvested at 4000 r.p.m. using an SS34 rotor in a Sorvall RC35 centrifuge for 4 min and washed twice with PBS and treated with 1:10 formaldehyde (37%) in PBS for 45 min at room temperature. Subsequently, the cells were washed and resuspended in a buffer containing sorbitol, sodium citrate, EDTA, 100 mg/ml zymolyase, glusulase and b-mercaptoethanol, and incubated at 30°C for 1 h. Cells were then adhered to poly-L-lysine-coated slides and ®xed with chilled methanol and acetone. Antibody against the N-terminal domain of the LdTOP2 (1:25 dilution) was used along with 3% BSA to detect the expressed proteins. Following the ®rst antibody reaction, slides were washed with PBS and reacted with¯uorescein isothiocyanate (FITC)-conjugated goatderived anti-rabbit IgG (1:100 dilution) for 45 min. After the last wash with PBS, the cells were mounted in 10% glycerol in PBS containing 0.1% p-phenylenediamine to prevent fading. To locate the yeast nucleus the ®xed cells were stained with ethidium bromide (0.25 mg/ml in PBS containing 10% glycerol). Cells were viewed with a TCS-SP Leica confocal microscope system equipped with a krypton±argon mixed laser.
Molecular modeling
A three-dimensional model of L.donovani topoisomerase II protein was obtained from Swiss Prot (37) . Energy minimizations were done on this model with a convergence criterion of 0.001 kcal/mol using a combination of steepest descent and conjugate gradient methods of 100 steps each. Secondary structures were analyzed using the programs Ribbons and Modelyn (38) and electrostatic potential surface of the model was determined by using MOL MOL (39) .
RESULTS
The CTD of L.donovani topoisomerase II
In order to study the CTD of L.donovani topoisoimerase II, the amino acid sequence of the enzyme was compared with that of S.cerevisiae and Homo sapiens using CLUSTAL W (40) . Figure 1 shows regions of alignment of amino acids of L.donovani topoisomerase II with that of the above two species. Sequence comparison shows that L.donovani topoisomerase II shares much lower identity and similarity of 23 and 31% with its yeast counterpart and an identity and similarity of 32 and 47% with its counterpart from human. The degree of conservation is generally greater in the N-terminal two-thirds of the coding sequence and falls off markedly towards the C-terminus. The poor homology between these two proteins suggests a weak evolutionary parsimony consistent with the evolutionary distance between Leishmania and other organisms. In L.donovani topoisomerase II, the variable C-terminal region covers approximately 400 amino acids extending from an approximate 850 amino acid residue, as observed from the multiple alignment analysis.
Effects of deletion on complementation ability
To investigate the role of the CTD of L.donovani topoisomerase II we have used a functional complementation assay of LdTOP2 deletion mutants to rescue a S.cerevisiae topoisomerase II temperature-sensitive mutant strain. The rationale for the use of S.cerevisiae was based on a number of factors. Like L.donovani, S.cerevisiae is a unicellular eukaryote and provides the most ef®cient eukaryotic system to test large numbers of mutations in an essential gene for effects on functional complementation. We constructed mutants of LdTOP2 that were serially deleted at the 3¢ end of the gene (Fig. 2A) . The C-terminus was subdivided into ®ve regions by six truncation mutants. We have used a plasmid-shuf¯ing technique to study the ability of wild-type and mutant forms of the LdTOP2 gene to complement the temperature-sensitive S.cerevisiae strain RS192 by in vivo complementation assay.
Plasmids expressing wild-type or mutant forms of the LdTOP2 gene were constructed with amino acid residues ranging from 1236 to 785 in a shuttle vector pVT100U and transformed into the temperature-sensitive URA ± yeast strain RS192 and URA + colonies were selected. RS192 and the cells transformed with pVT100U served as controls, respectively, in the complementation assays. At the non-permissive temperature (37°C), there was complementation with the full-length LdTOP2 gene containing 1236 amino acids. When 40 and 118 amino acids from the C-terminus were removed by truncation to residues 1195 (LdDC1195) and 1118 (LdDC1118), no detectable effects on the ability of the mutant enzymes to complement S.cerevisiae were found. Truncation to residue 1058 (LdDC1058) causes only slightly impaired growth of the host strain. However, any truncation beyond residue 1058 towards the N-terminus (LdDC998 and LdDC785) completely abolished growth of the yeast strain at the non-permissive temperature (Fig. 2B) .
Our observation adds to the general conclusion that topoisomerase II enzyme from a wide variety of eukaryotic origins are functionally interchangeable (41±45) and that only a part of the divergent CTD of the enzyme is dispensable for catalytic activity (15) .
Stability of transcripts, protein expression and in vitro activity
It is not known whether the inability to complement by some of the constructs is due to reduced gene expression or due to enhanced proteolysis of the gene products or due to synthesis of inactive proteins. RT±PCR analysis was performed using speci®c primers for the N-terminal 1.1 kb region of the LdTOP2 gene. Total RNA was isolated from the yeast cells harboring the full-length and the truncated LdTOP2 constructs. The yeast cell RS192 was taken as a negative control. RT±PCR performed with the primers for the housekeeping tubulin gene of S.cerevisiae served as a positive control. As shown in Figure 3A , the transcripts from the yeast cells harboring the wild-type and the mutant LdTOP2 were expressed at similar levels comparable with the housekeeping tubulin of S.cerevisiae. Western blot analysis using the antibody raised against the N-terminal 1.1 kb region of LdTOP2 (43 kDa protein) shows that the wild-type and different topoisomerase II mutant proteins were also expressed at similar levels (Fig. 3B ). Our observations thus suggest that the level of transcripts does not correlate with the lack of complementation.
The ability of an enzyme to complement a genetic de®ciency usually re¯ects the ability of the enzyme to perform catalysis. The recombinant enzymes LdTOP2, LdDC1195, LdDC1118 and LdDC1058 from crude yeast extracts were able to perform decatenation of the kDNA in vitro. That the observed decatenation of the kDNA was not due to nuclease activity was substantiated by the inhibition of decatenation activity by etoposide, an eukaryotic topoisomerase II inhibitor (Fig. 3C) . As the yeast cell harboring the constructs LdDC998 and LdDC785 failed to survive at the non-permissive temperature, the truncated proteins from LdDC998 and LdDC785 were expressed in E.coli and induced as described in Materials and Methods. The crude bacterial extracts failed to decatenate the kDNA networks into minicircles. As the truncated transcripts are expressed at similar levels, the inability to complement correlates well with the loss of decatenation activity of the parasite enzyme. The results of complementation, protein expression and decatenating activity of the wild-type and mutant enzymes in yeast are summarized in Table 1 .
Distribution of wild-type and mutant L.donovani topoisomerase II in yeast
Since topoisomerase II activity is required within the nucleus and it is known that the C-terminus of several eukaryotic topoisomerase II enzymes contains nuclear import signal, we examined the ability of the wild-type and the mutant enzymes to be translocated to the nucleus. Indirect immuno¯uorescence was carried out to show the distribution of the mutant proteins and of the full-length LdTOP2 enzymes in yeast cells. To eliminate the cross-reactivity of the antibody with the yeast TOP2, the yeast strain RS192 was taken as negative control. There was no detectable signal from control cells harboring pVT100U (data not shown). The only signal detected in cells expressing full-length, LdDC1195 and LdDC1118 enzymes was from the nucleus (Fig. 4A±C) , which is identi®ed by ethidium bromide staining and the overlapping area of the FITC and the ethidium bromide stain. The enzyme LdDC1058 is also localized in the nucleus, albeit with lesser ef®ciency (Fig. 4D) . Any further deletion to residue 998 (LdDC998) and 785 (LdDC785) abolished the speci®c nuclear staining and the truncated enzymes were localized only in the cytoplasm as indicated by a non-overlapping area of the FITC and ethidium bromide stain ( Fig. 4E and F) . Thus, a major NLS appears to be localized between residues 1058 and 998, although this may not be the only functional signal in the parasite enzyme. Our immuno¯uorescence results are consistent with the interpretation that nuclear localization is likely to be one contribution of the CTD to the physiological function of type II DNA topoisomerase from L.donovani.
Three-dimensional model of LdTOP2
The model of LdTOP2 was obtained from Swiss Prot (37) based on the crystal structure of yeast type II DNA topoisomerase (12) . The model consists of amino acid residues from 410 to 1116. Like its yeast counterpart, it has the shape of a¯attened crescent. The polypeptide chain folds into two subfragments denoted B¢ and A¢. B¢, which corresponds to the B¢ sub-fragment of gyrase contains residues 410±624, whereas A¢ contains residues 675±1116. The highly conserved amino acid motifs of TEGDSAK and APRYIFT (harboring the catalytic tyrosine residue in the active site pocket) were found to be sequentially and conformationally conserved in the LdTOP2 model as in other prokaryotic and eukaryotic type II DNA topoisomerases (Fig. 5A) .
The dimer is formed by placing the two crescent-shaped monomers in close proximity by symmetry operation. The two monomers form a heart-shaped cavity that can encircle a DNA duplex. A putative dimerization interface has been described on the basis of the yeast crystal structure. In our threedimensional model, the predicted points of contact in the dimer are between the regions 1022±1037 and 1056±1071 in the A¢ sub-fragment. The V-shaped A¢-A¢ dimer in turn receives the B¢-B¢ dimer at its open end; this protein arch caps the hole between the two A¢ domains. The B¢-B¢ dimer contact is less extensive than the A¢-A¢ interface. The two B¢ subfragments curl about each other, with each of the smaller domains contacting the larger domains of the other subfragment. Although some of the contacts involve relatively variable residues, the most intimately associated region (Ile529, Leu540, Ile547 and Tyr593) is quite well conserved (Fig. 5B) . Comparison of the electrostatic potential of the entire monomer of the two enzymes shows that the two proteins have nearly similar charge distribution (Fig. 6A and B) . The model reveals a span of 60 amino acids ranging from 998 to 1058 (marked in red), at the C-terminus of the A¢ sub-fragment and shows a marked difference in the distribution of charge (Fig. 6C) . This region of the parasite protein has a strong positive potential as compared with its yeast counterpart. The important feature highlighted in the model is the putative dimer interface of the Leishmania enzyme and a span of 60 amino acids (998±1058) distinctly different from its yeast counterpart. 
DISCUSSION
The nature of the multi-domain structure for eukaryotic topoisomerase II is revealed by many lines of evidence, including sequence comparison, mutagenesis and X-ray crystal structures (18, 20) . Although the topoisomerase II genes from the kinetoplastid parasites have been cloned and sequenced (24±26,29) very little is known about the characteristics of the protein. At ®rst sight, protozoan topoisomerases appear to share many characteristics of their human homologs, but closer observation reveals that differences do exist. Alignment of the sequences of the type II DNA topoisomerase of yeast, human and L.donovani has revealed conservation at the N-terminal region of the enzyme and the conservation decreases towards the CTD (Fig. 1) . The CTDs are only similar in sequences for closely related species and that too for the ®rst half of the tail (29, 46) . A number of studies have focused on identifying domains in eukaryotic TOP2 interacting speci®cally with anti-TOP2 agents (47) . So, in this study we have tried to assess the importance of the CTD of LdTOP2, which is the largest unconserved domain of topoisomerase II.
Deletion of conserved domains in human TOPIIa and S.cerevisiae TOP2 have led to inactive, non-complementing proteins indicating that all conserved domains are important for TOP2 function (15) . Only a part of the CTD of human TOPIIa, S.cerevisiae and Drosophila melanogaster is dispensable for complementation in S.cerevisiae (15, 48) . So, a number of C-terminal truncation mutants of LdTOP2 deleted to amino acid residue 785 were constructed. Survival of a temperature-sensitive topoisomerase II mutant yeast strain in the presence of LdTOP2 at the non-permissive temperature should be all-or-nothing. None of the mutants beyond 1058 amino acid residues were able to complement for the temperature sensitivity of the mutant yeast strain (Fig. 2B) .
The C-terminus of eukaryotic TOP2 contains many regulatory elements like the phosphorylation sites (14, 49) , dimerization domain (15, 16) and the NLSs (13) . It is known for many genes that the deletion of sequences leads to unstable messenger RNAs and may also affect protein expression or stability. To rule out the possibility that the observation made on complementation ability was due to low expression or instability of certain truncated transcripts, RT±PCR was performed (Fig. 3A) . Transcripts of all the constructs were obtained at a similar level showing that the full-length CTD of LdTOP2 is not required for the stability of the transcript. Immunoblot experiments show the presence of only a single band in the expected regions in all the crude extracts isolated from recombinant yeast cells carrying wild-type and truncated Leishmania topoisomerase II genes (Fig. 3B) . Our data indicate that all the wild-type and truncated LdTOP2 proteins are expressed at similar levels showing that C-terminal deletion does not alter the stability of the protein nor does it render the protein susceptible to proteolytic degradation (Fig. 3B ). Previous studies with human TOPIIa and S.cerevisiae TOP2 indicate that lack of complementation does not correlate with loss of catalytic activity (15) . Our studies reveal that the LdTOP2 mutants which fail to complement the mutant yeast strain in vivo also fail to decatenate kDNA in vitro. It is likely that the lack of catalytic activity of the C-terminal truncation mutants LdDC998 and LdDC785 is due to the inability of the subunit to form dimers. The C-terminus of the topoisomerase II contains NLSs. Alternatively, the C-terminus may be a regulatory domain or it may provide a site for the interaction with DNA and RNA (50) . The localization study was performed with the truncated proteins to seek a potential function of the CTD. It was found that the full-length enzyme and the enzyme truncated to 1118 residues are localized within the nucleus in the yeast cell, whereas the enzyme truncated to residue 1058 was only partially impaired with respect to nuclear translocation (Fig. 4A±D) . However, the non-complementing enzyme truncated to residue 998 and 785, appeared to localize only in the cytoplasm, indicating its failure to be translocated to the nucleus in yeast (Fig. 4E and F) . This observation suggests the existence of a major NLS KRRRTRKIGL between amino acid residues 998 and 1058. In human, a suggested nuclear signal (KKQTTLAFKPIKKGKKR) is located between residues 1274 and 1290 (13) . Identi®cation of a region containing the putative NLS in the highly variable C-terminal part of LdTOP2 correlates well with the previous studies on type II DNA topoisomerases from H.sapiens (13, 15) , mouse (42), S.pombe (19, 51) , D.melanogaster (48) and S.cereviseae (52) .
The model of LdTOP2 based on the available crystal structure of yeast TOP2 (PDB accession no. 1BJT) shows that the parasite protein adopts an overall conformation similar to yeast TOP2 and is organized into two sub-fragments A¢ and B¢. All the secondary structural elements are conserved between the two proteins and are present in structurally relative positions (Fig. 5A) . Placing the two monomers in close proximity reveals a putative dimer interface in a structurally equivalent position to that of the crystallized yeast TOP2 (Fig. 5B) . The crystal structure reveals two dimerization regions where the primary dimer interface is present in the C-terminal part of the fragment involving residues 1031±1046 and 1114±1130. A biochemical approach identi®es two regions spanning amino acid residues 1053± 1069 and 1124±1143 essential for the dimerization of human TOPIIa. Our model reveals a putative dimer interface, which is formed between the amino acid residues 1022±1037 and 1056±1071.
Although the mutant LdDC1058 contains one primary dimerization region and three amino acid residues of the second dimerization region, it can still complement a mutant yeast cell albeit with lesser ef®ciency and can decatenate kDNA in vitro. Since this region tolerates linker insertion in both yeast and human (15) , it indicates that this area might constitute a¯exible structure. Taken together, our results suggest that the enzyme deleted to residue 998 cannot functionally complement the mutant yeast strain, as it cannot be translocated to the nuclear compartment where the enzyme needs to carry out its function.
The current drugs for leishmaniasis infection are inadequate due to low ef®cacy or high toxicity and the problem is further compounded by the emergence of increasingly pentavalent antimonial drug-resistant parasites (53) . The search for an ef®cacious, less toxic, yet inexpensive drug, is the requirement of the day to ®ght against leishmaniasis. DNA topoisomerases have been established as important chemotherapeutic targets for various anticancer (54) , antibacterial (55) , antiviral (56) and antiparasitic agents (57) . If a protein or a pathway is conserved between the mammalian host and the pathogen, some discriminating features that distinguish between the host and the pathogen system must be identi®ed. Recently, from our laboratory, various antileishmanial agents have been reported which target the parasite topoisomerases (57, 58) . For parasitic topoisomerases to be targeted selectively by speci®c agents, suf®cient differences should exist between them and their human homolog to enable them to be pharmacologically distinguishable. Our analysis of mutants truncated at the C-terminus of L.donovani indicates that the amino acid residues between 998 and 1058 are very essential for the protein in vivo. While deletion of more than 1058 amino acid residues from the C-terminus results in complete loss of topoisomerase function, mutants with shorter deletions such as LdDC1195 and LdDC1118 can functionally complement yeast topoisomerase II in in vivo assays. The residues between 998 and 1058, encompassing a span of 60 amino acids, reveal a critical point in the sequence of LdTOP2. A Blast search shows that these 60 amino acid residues share no similarity with the host TOP2 or any other eukaryotic protein. The level of sequence and structure conservation between the host and the parasite enzyme is high. However, there is a noteworthy difference in this region of the CTD.
Topoisomerase II is a highly potential drug target because it has an indispensable function in cell biology and it lacks biological redundancy. A future aspect of this work lies in exploiting the differences between the CTD of the host and parasite enzyme by integrating structural information with biochemical experimentation, so as to delineate the common and distinguishing feature of the host and parasite enzyme. This information will provide an insight for development of newer therapeutic agents with speci®c selectivity.
